The Readout Loud
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Horizon Therapeutics and what it means for the drug industry. We also discuss the latest on Sarepta Therapeutics and its gene therapy for Duchenne muscular dystrophy, a turnaround story in the making at the Belgian drug maker Galapagos, and the effort to secure approval for a maternal RSV vaccine.